about us

To develop transformative biological therapies that restore chronic wounds, starting with diabetic foot ulcers.

The need is urgent, and current treatments often fall short.

At Omnio, we harness the unique power of plasminogen to unlock new therapies for chronic wounds and inflammation.
Starting with diabetic foot ulcers, our biologically driven platform is paving the way toward better healing,
reduced scarring, and a future free from persistent infections.

Our therapy is built on decades of research at Umeå University, where Professor Tor Ny uncovered the essential role
of plasminogen in wound healing. Now, our team expands from Sweden, to Spain, the UK, Denmark and India.

We are getting ready to perform our phase IIa/b trials in 2026 and 2027.

We are scientists, clinicians, and entrepreneurs with deep expertise in regenerative biology, chronic inflammation,
and drug development—with a proven track record in global wound care innovation

Our team combines translational research, biotech strategy, clinical strategy and manufacturing readiness.
With the support of a strong board and academic partners, we’re building a company built to scale—and built to last.

Management team

Felipe Velasquez

CEO

Felipe Velasquez is a seasoned Life Sciences executive with over 25 years of experience driving strategic growth and operational excellence in the pharmaceutical, biotech and healthcare sectors.

His track record includes launching and scaling ventures across pharmaceuticals, diagnostics, and healthcare specialty networks. He has successfully led M&A initiatives, out licensing deals, forging strategic partnerships, and optimizing business operations for sustainable expansion.

With a strong foundation in finance, marketing, and operations, Felipe brings a global perspective, having worked across eight European countries, the U.S., Latin America, and India. His ability to drive innovation and execute strategic initiatives makes him a valuable leader in the biotech and healthcare industries.

Read less

Tor Ny

Founder – Head of RnD

Tor Ny is a senior professor in Medical Biochemistry with over 30 years of research experience exploring the therapeutic potential of plasminogen in wound healing.

A pioneer in the field, Tor Ny was among the first to demonstrate the regenerative effects of plasminogen as a wound healing drug candidate. His extensive academic and clinical work has helped unlock the role of plasminogen across multiple therapeutic indications.

With a deep commitment to advancing science, he has contributed significantly to the understanding of inflammation resolution, tissue repair, and the biological pathways that underlie natural healing processes. His research forms a key part of Omnio’s scientific foundation.

Read less

Henrik Bergdahl

Chief financial officer

Experienced accountant with a track record of financial reporting and management within numerous life science companies.

Joanne James

Excecutive Director Clinical Development

Joanne is a multi-award-winning innovator with over 25 years of experience driving clinical strategy and development in medical devices and pharmaceuticals.

She has played a pivotal role in product development, pre-clinical and clinical program design, and execution—leading to multiple strategic acquisitions and regulatory approvals in the wound care field.

Recent achievements include leading evidence generation that contributed to Convatec’s acquisition of Thirty Technology’s wound franchise in 2023, and advancing pre-clinical studies supporting FDA approval of Filsuvez for Epidermolysis Bullosa (Amryt Pharma, 2022).

Read less

Anders Vagnø Pedersen

CMC manager

Anders is a Senior CMC Advisor with over 35 years of experience in the Biotech and Pharma industry, specializing in process development and CMC documentation.

Throughout his career, Anders has built deep expertise across upstream and downstream process development, formulation, patent strategy, and project management.

He has successfully led multiple GMP CMC product filings across Europe, the U.S., and Japan, bringing a strong track record in navigating CMC related regulatory pathways and ensuring quality and compliance throughout the development cycle.

Read less

Board of Directors

Thomas Würdinger

Professor Neuroscience, biotech entrepreneur

Thomas is a molecular cell biologist and serial entrepreneur with a strong academic and start-up background.

After conducting research at Harvard, he established a research group in Amsterdam and was appointed professor at the age of 35. His academic foundation laid the groundwork for a successful transition into biotech entrepreneurship.

He played a founding role in GRAIL and has since been active in supporting early-stage innovation through his investment fund, Reunion Capital—bringing Silicon Valley experience to the next generation of breakthrough ventures.

Read less

Charlotta Gummeson

Senior life science executive

Experienced healthcare professional with a 20-year background in Sales & Marketing, Communication, and International Business Management.

Over the past two decades, this professional has held key leadership roles across global healthcare organizations, specializing in driving commercial strategy and cross-border communications within complex business environments.

In addition to a commercial background, they bring 6 years of experience in Investment Management—focused on equity capital and high-growth companies. Through active board participation and owner representation, they have helped shape strategic direction and scale potential across emerging ventures.

Read less

Robert Al

Tech transfer specialist

Robert has been active in academic technology transfer since 2003 and currently leads the technology transfer office at Erasmus University Medical Center in Rotterdam.

He has held multiple executive roles across Dutch universities and played a key role in founding over 50 companies emerging from academic research. His experience spans commercialization strategy, venture creation, and deal-making in the life sciences sector.

Robert also served as CFO of the biotech startup thromboDx, a spinout from Vrije Universiteit Amsterdam, which was successfully acquired by a major diagnostics company listed on the Nasdaq.

Read less

Matthew Rondina

Translational science

Dr. Matthew Rondina is a physician-scientist, biotech entrepreneur, and Professor of Medicine & Pathology at the University of Utah.

As Executive Director for the Molecular Medicine Program, he leads multidisciplinary teams advancing platform technologies in hematology, immunology, oncology, and precision medicine. He is also the founder of a molecular diagnostics company that leverages platelet RNA and AI to enable early cancer detection through clinically actionable insights.

Dr. Rondina brings over 15 years of translational leadership across academic and commercial domains. He advises biotech companies at every stage—from preclinical development to trial design, regulatory strategy, and commercial launch. His work has contributed to the advancement of cell therapies, monoclonal antibodies, and RNA-based diagnostics.

An elected member of the American Society for Clinical Investigation (ASCI), he has authored more than 200 peer-reviewed publications, been invited to speak at over 100 conferences, and served as a strategic advisor to more than 25 organizations worldwide.

Read less

Tor Ny

Founder – Head of RnD

Tor Ny is a senior professor in Medical Biochemistry with over 30 years of research experience exploring the therapeutic potential of plasminogen in wound healing.

Read less

Jos van der Woert

Marketing & regulatory specialist big pharma

Jos is a senior pharmaceutical executive with deep leadership experience, particularly in the field of Oncology.

He is the founder of OncoLogics LLC, a strategic advisory firm supporting the biopharmaceutical industry, which he launched in 2010 after retiring from Schering-Plough Corporation following its acquisition by Merck & Co.

From 2003 to 2010, Jos served as global head of the oncology and hepatitis/HIV franchises at Schering-Plough, overseeing worldwide commercial operations, sales, marketing, and business development. Prior to that, he held senior leadership roles at Pfizer/Pharmacia and Bristol-Myers Squibb, working across both Europe and the United States.

Read less